Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Biomarkers Advanced Technologies Market

ID: MRFR/HC/20202-HCR
128 Pages
Rahul Gotadki
Last Updated: April 06, 2026
United States Biomarkers Advanced Technologies Market Research Report Information By Application (Risk Assessment, Development of Molecular Diagnostics, Disease Diagnosis, Drug Discovery and Development, Drug Formulation, Forensic Application, Others (DNA fingerprinting and others)), By Indication (Cancer, Infectious Diseases, Immune Disorders, Neurological Disorders, Cardiovascular Disorders, Other Disease Indications), By End User (Pharmaceutical and Biotechnology Companies, Diagnostics and Research Laboratories, Hospitals, Specialty Clinics, Others)– United States Market Forecast Till 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Billion)
      1. 4.1.1 Oncology
      2. 4.1.2 Cardiology
      3. 4.1.3 Neurology
      4. 4.1.4 Infectious Diseases
      5. 4.1.5 Metabolic Disorders
    2. 4.2 Healthcare, BY Technology (USD Billion)
      1. 4.2.1 Genomics
      2. 4.2.2 Proteomics
      3. 4.2.3 Metabolomics
      4. 4.2.4 Immunoassays
      5. 4.2.5 Bioinformatics
    3. 4.3 Healthcare, BY End Use (USD Billion)
      1. 4.3.1 Pharmaceutical Companies
      2. 4.3.2 Research Institutions
      3. 4.3.3 Diagnostic Laboratories
      4. 4.3.4 Clinical Laboratories
      5. 4.3.5 Biotechnology Companies
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Thermo Fisher Scientific (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Roche Diagnostics (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Abbott Laboratories (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Illumina (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Agilent Technologies (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Bio-Rad Laboratories (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 PerkinElmer (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Qiagen (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Merck KGaA (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
      10. 5.2.10 SAB Biotherapeutics (US)
        1. 5.2.10.1 Financial Overview
        2. 5.2.10.2 Products Offered
        3. 5.2.10.3 Key Developments
        4. 5.2.10.4 SWOT Analysis
        5. 5.2.10.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY APPLICATION
    3. 6.3 US MARKET ANALYSIS BY TECHNOLOGY
    4. 6.4 US MARKET ANALYSIS BY END USE
    5. 6.5 KEY BUYING CRITERIA OF HEALTHCARE
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF HEALTHCARE
    8. 6.8 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    10. 6.10 SUPPLY / VALUE CHAIN: HEALTHCARE
    11. 6.11 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    12. 6.12 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    13. 6.13 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
    15. 6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
      2. 7.2.2 BY TECHNOLOGY, 2026-2035 (USD Billion)
      3. 7.2.3 BY END USE, 2026-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2026-2035)

  • Oncology
  • Cardiology
  • Neurology
  • Infectious Diseases
  • Metabolic Disorders

Healthcare By Technology (USD Billion, 2026-2035)

  • Genomics
  • Proteomics
  • Metabolomics
  • Immunoassays
  • Bioinformatics

Healthcare By End Use (USD Billion, 2026-2035)

  • Pharmaceutical Companies
  • Research Institutions
  • Diagnostic Laboratories
  • Clinical Laboratories
  • Biotechnology Companies